Patents Assigned to Epicyte Pharmaceutical, Inc.
  • Publication number: 20040199945
    Abstract: Arrays of immunoglobulin binding proteins in plants or plant cells are provided. Such arrays comprise plants or plant cells transformed with polynucleotides encoding multiple different immunoglobulin binding proteins, or polypeptide components thereof. Methods are further provided for genetic segregation of the transformation events such that each transformant in an array is capable of producing progeny capable of expressing one or more immunoglobulin binding proteins, including multi-subunit proteins.
    Type: Application
    Filed: February 19, 2004
    Publication date: October 7, 2004
    Applicant: Epicyte Pharmaceutical, Inc.
    Inventors: Andrew C. Hiatt, Mitch B. Hein
  • Patent number: 6696620
    Abstract: Arrays of immunoglobulin binding proteins in plants or plant cells are provided. Such arrays comprise plants or plant cells transformed with polynucleotides encoding multiple different immunoglobulin binding proteins, or polypeptide components thereof. Methods are further provided for genetic segregation of the transformation events such that each transformant in an array is capable of producing progeny capable of expressing one or more immunoglobulin binding proteins, including multi-subunit proteins.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: February 24, 2004
    Assignee: Epicyte Pharmaceutical, Inc.
    Inventors: Andrew C. Hiatt, Mich B. Hein
  • Publication number: 20030224443
    Abstract: Targeting molecules are provided for use in delivering imaging agents to epithelial tissue. The targeting molecule comprises a polypeptide that forms a closed covalent loop, contains at least three peptide domains having &bgr;-sheet character, each of the domains being separated by domains lacking &bgr;-sheet character. The targeting molecule specifically binds to a basolateral factor attached to a basolateral domain of an epithelial cell surface causing internalization of a linked imaging agent into the cells. The polypeptide or imaging agent may be linked to a peptide amino acid sequence that directs delivery of the imaging agent to a carcinoma cell, a nucleus, or an endoplasmic reticulum.
    Type: Application
    Filed: February 5, 2002
    Publication date: December 4, 2003
    Applicant: Epicyte Pharmaceutical, Inc.
    Inventors: Andrew C. Hiatt, Mich B. Hein, John H. Fitchen
  • Patent number: 6440419
    Abstract: Targeting molecules for use in delivering biological agents to non-polarized epithelial cells are disclosed. Upon delivery, the biological agent(s) are lethal to the epithelial cell. The targeting molecules may be used, for example, for the eradication of metastatic epithelial cells.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: August 27, 2002
    Assignee: Epicyte Pharmaceutical, Inc.
    Inventors: Mich B. Hein, Andrew C. Hiatt, John H. Fitchen
  • Patent number: 6391280
    Abstract: Polypeptide targeting molecules are provided for use in delivering imaging agents to epithelial tissue. Upon delivery, the imaging agent(s) may remain within an epithelial cell or may undergo transepithelial transport via transcytosis. The targeting molecules may be used, for example, for diagnostic techniques. The polypeptide may be produced by recombinant methods, and forms a closed covalent loop, contains at least three peptide domains having &bgr;-sheet character which are separated by domains lacking &bgr;-sheet character, specifically binds to a basolateral factor attached to a basolateral domain of an epithelial surface causing uptake of a linked imaging agent into cells of the epithelial surface, and is not a full length dimeric Iga. Preferably, the polypeptide is a J chain polypeptide, or a J chain polypeptide linked to an immunoglobulin heavy chain without an immunoglobulin light chain.
    Type: Grant
    Filed: January 9, 1998
    Date of Patent: May 21, 2002
    Assignee: Epicyte Pharmaceutical, Inc.
    Inventors: Andrew C. Hiatt, Mich B. Hein, John H. Fitchen
  • Patent number: 6251392
    Abstract: Targeting molecules for use in delivering biological agents to non-polarized epithelial cells are disclosed. Upon delivery, the biological agent(s) are lethal to the epithelial cell. The targeting molecules may be used, for example, for the eradication of metastatic epithelial cells.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: June 26, 2001
    Assignee: Epicyte Pharmaceuticals, Inc.
    Inventors: Mich B. Hein, Andrew C. Hiatt, John H. Fitchen
  • Patent number: 6045774
    Abstract: Targeting molecules for use in delivering imaging agents to epithelial tissue are disclosed. Upon delivery, the imaging agent(s) may remain within an epithelial cell or may undergo transepithelial transport via transcytosis. The targeting molecules may be used, for example, for diagnostic techniques. The targeting molecule is a polypeptide, which may be produced by recombinant methods, that forms a closed covalent loop, contains at least three peptide domains having .beta.-sheet character which are separated by domains lacking .beta.-sheet character, specifically binds to a basolateral factor attached to a basolateral domain of an epithelial surface causing uptake of a linked imaging agent into cells of the epithelial surface, and is not a full length dimeric Iga. Preferably, the polypeptide is a J chain polypeptide, or a J chain polypeptide linked to an immunoglobulin heavy chain without an immunoglobulin light chain.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: April 4, 2000
    Assignee: EPIcyte Pharmaceutical Inc.
    Inventors: Andrew C. Hiatt, Mich B. Hein, John H. Fitchen